Journey Colab

Actual: Jan 1, 2020

Founded by Dr Jeeshan Chowdhury and Jennifer Pisansky; $3M seed from Apollo Projects (Sam Altman's moonshot fund)

Why it matters: First company to pursue synthetic mescaline through FDA clinical development. Apollo Projects backing (Sam Altman) signals Silicon Valley interest in psychedelic medicine for addiction.

Actual: Oct 1, 2022

$12M Series A raised (total $15M); preclinical and CMC programmes completed

Why it matters: Well-capitalized for Phase 1 entry. Preclinical and chemistry/manufacturing/controls completion means JOUR-5700 is Phase 1-ready from a drug development perspective.

Actual: Oct 1, 2022

Nature profile published on mescaline clinical development and Journey Colab's approach

Why it matters: Nature coverage validates the scientific rationale for mescaline in AUD. Mescaline is the only classical psychedelic with no modern clinical trial data — it was studied extensively in the 1950s-60s for alcoholism but never progressed through modern regulatory frameworks.

Actual: Dec 1, 2023

Last known public activity — no press releases, no NCT registered, no trial recruitment announced since late 2023

Why it matters: Phase 1 at CHDR was expected to begin by 2023 but appears not to have started. Over 2 years of silence is concerning. Company is still listed as active on PitchBook/Crunchbase with $15M total raised. May be in stealth-mode development or facing funding/regulatory challenges.

Watch next: Phase 1 trial registration on ClinicalTrials.gov; CHDR site activation; any press release or funding announcement